INmune Bio surges ahead of mid-stage trial readout for Alzheimer’s drug

1 week ago 1

• Healthcare
• On the Move

travellinglight/iStock via Getty Images

• Shares of INmune Bio (NASDAQ:INMB) extended after-hours gains in the pre-market trading on Friday with a ~61% rise as Wall Street reacted to a company event scheduled next week to disclose mid-stage trial data for its Alzheimer’s drug XPro.
• The

Recommended For You

More Trending News

See More »

1. Homepage
2. Politics
3. INmune Bio surges ahead of mid-stage trial readout for Alzheimer’s drug